Back Article

  • Bock L C, Griffin L C, Latham J A. Selection of single-stranded DNA molecules that bind and inhibit human thrombin[J]. Nature, 1992, 355(6360): 564-566. doi: 10.1038/355564a0

  • Brody E N, Gold L. Aptamers as therapeutic and diagnostic agents[J]. J Biotechnol, 2000, 74(1): 5-13.

  • Chapman J A, Beckey C. Pegaptanib: A novel approach to ocular neovascularization[J]. Ann Pharmacother, 2006, 40(7-8): 1322-1326. doi: 10.1345/aph.1G604

  • Chu C M, Liaw Y F. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/mem-branous hepatitis B core antigen as a possible target for immune hepatocytolysis[J]. Gastroenterology, 1987, 92(): 220-225. doi: 10.1016/0016-5085(87)90863-8

  • Chu T C, Twu K Y, Ellington A D. Aptamer mediated siRNA delivery[J]. Nucleic Acids Res, 2006, 34(10): e73-. doi: 10.1093/nar/gkl388

  • Connell G J, Illangesekare M, Yarus M. Three small ribooligonucleotides with specific arginine sites[J]. Biochemistry, 1993, 1;32(21): 5497-502.

  • Dienstag J L. Looking to the future: new agents for chronic hepatitis B[J]. Am J Gastroenterol, 2006, 101(): S19-S25. doi: 10.1111/ajg.2006.101.issue-s1

  • Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands[J]. Nature, 1990, 30;346(6287): 818-822.

  • Gish R G. Current treatment and future directions in the management of chronic hepatitis B viral infection[J]. Clin Liver Dis, 2005, 9(): 541-565. doi: 10.1016/j.cld.2005.08.005

  • Guan R. Treatment of chronic hepatitis B infection using interferon[J]. Med J Malaysia, 2005, 60(): 28-33.

  • Hicke B J, Marion C, Chang Y F. Tenascin-C aptamers are generated using tumor cells and purified protein[J]. J Biol Chem, 2001, 28; 276(52): 48644-48654.

  • Hicke B J, Stephens A W. Escort aptamers: a delivery service for diagnosis and therapy[J]. J Clin Invest, 2000, 106(8): 923-928. doi: 10.1172/JCI11324

  • Jayasena S D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics[J]. Clin Chem, 1999, 45(9): 1628-1650.

  • Jenison R D, Jennings S D, Walker D W. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion[J]. Antisense Nucleic Acid Drug Dev, 1998, 8(4): 265-279. doi: 10.1089/oli.1.1998.8.265

  • Khaled A, Guo S, Li F. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Letters, 2005, 5(9): 1797-1808. doi: 10.1021/nl051264s

  • Kojima T. Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes[J]. Gastroenterol Jpn, 1982, 17(): 559-575.

  • Liu C J, Liou J M, Chen D S. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections[J]. J Formos Med Assoc, 2005, 104(): 783-791.

  • Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B[J]. J Viral Hepat, 2005, 12(): 333-345. doi: 10.1111/jvh.2005.12.issue-4

  • McNamara J O 2nd, Andrechek E R, Wang Y. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras[J]. Nat Biotechnol, 2006, 24(8): 1005-1015. doi: 10.1038/nbt1223

  • Ng E W, Shima D T, Calias P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease[J]. Nat Rev Drug Discov, 2006, 5(2): 123-132. doi: 10.1038/nrd1955

  • Ocama P, Opio C K, Lee W M. Hepatitis B virus infection: current status[J]. Am J Med, 2005, 118(): 1413-.

  • Onishi S, Saibara T, Ito K. Hepatitis B surface antigen specific cytotoxic T lymphocyte activity in hepatitis B virus infection[J]. Gastroenterol Jpn, 1985, 20(): 330-337.

  • Pagratis N C, Bell C, Chang Y F. Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor[J]. Nat Biotechnol, 1997, 15(1): 68-73. doi: 10.1038/nbt0197-68

  • Perrillo R P. Current treatment of chronic hepatitis B: benefits and limitations[J]. Semin Liver Dis, 2005, 25(): 20-28. doi: 10.1055/s-2005-915647

  • Rhodes A, Deakin A, Spaull J. The generation and characterization of antagonist RNA aptamers to human oncostatin M[J]. J Biol Chem, 2000, 275(37): 28555-28561. doi: 10.1074/jbc.M002981200

  • Rhodes A, Smithers N, Chapman T. The generation and characterisation of antagonist RNA aptamers to MCP-1[J]. FEBS Lett, 2001, 506(2): 85-90. doi: 10.1016/S0014-5793(01)02895-2

  • Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection[J]. Curr Med Res Opin, 2005, 21(): 1845-1856. doi: 10.1185/030079905X65268

  • Ruckman J, Green L S, Beeson J. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain[J]. J Biol Chem, 1998, 273(32): 20556-20567. doi: 10.1074/jbc.273.32.20556

  • Rusconi C P, Scardino E, Layzer J. RNA aptamers as reversible antagonists of coagulation factor IXa[J]. Nature, 2002, 419(6902): 90-94. doi: 10.1038/nature00963

  • Sasaki H, Kojima T, Matsui S. Interaction of lymphocytes with hepatocytes containing hepatitis B antigen: ultrastructural demonstration of target antigen andT-cell subsets by the peroxidase antibody technique[J]. Virchows Arch A Pathol Anat Histopathol, 1987, 411(): 489-498. doi: 10.1007/BF00735232

  • Shu D, Guo P. A viral RNA that binds ATP and contains a motif similar to an ATP-binding aptamer from SELEX[J]. J Biol Chem, 2003, 278(9): 7119-7125. doi: 10.1074/jbc.M209895200

  • Simon K, Lingappa V R, Ganem D. Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor[J]. J Cell Biol, 1988, 107(): 2163-2168. doi: 10.1083/jcb.107.6.2163

  • Tian Y, Adya N, Wagner S. Dissecting protein:protein interactions between transcription factors with an RNA aptamer[J]. RNA, 1995, 1(3): 317-326.

  • Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase[J]. Science, 1990, 3; 249(4968): 505-510.

  • Watson S R, Chang Y F, O'Connell D. Anti-L-selectin aptamers: binding characteristics, phar-macokinetic parameters, and activity against an intravascular target in vivo[J]. Antisense Nucleic Acid Drug Dev, 2000, 10(2): 63-75. doi: 10.1089/oli.1.2000.10.63

  • Wiegand T W, Williams P B, Dreskin S C. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I[J]. J Immunol, 1996, 157(1): 221-230.

  • Wright T L. Introduction to chronic hepatitis B infection[J]. Am J Gastroenterol, 2006, 101(): S1-S6. doi: 10.1111/ajg.2006.101.issue-s1